{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T14:11:06Z","timestamp":1782310266246,"version":"3.54.5"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Uterine carcinosarcoma is a rare, aggressive biphasic tumor comprising both carcinomatous and sarcomatous elements. The overall prognosis of women with uterine carcinosarcoma is poor, with a median overall survival of less than two years. The predictors of survival for patients with uterine carcinosarcoma in the Kingdom of Saudi Arabia have not yet been fully elucidated; this study therefore explored the demographic features and prognostic factors of uterine carcinosarcoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This A cross-sectional study was conducted among all confirmed carcinosarcoma cases at Princess Noorah Oncology Center, National Guard Hospital, Jeddah, Saudi Arabia, from January 2003 to December 2023. Data were collected on demographic features, medical history, stage, treatment modality, and disease outcome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 34 patients with carcinosarcoma were identified, accounting for 4.7% of all endometrial cancer cases. Sixty percent of patients were diagnosed early, during stages 2B and below. The most common presentation was post-menopausal bleeding, occurring in 90% of the sample. Kaplan\u2013Meir analysis revealed an overall median survival of 14 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The findings confirmed the aggressiveness of the tumor. Late tumor stage was identified as a factor affecting patients\u2019 survival and outcome, being associated with poor prognosis and short survival time.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1594233","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T04:14:24Z","timestamp":1757045664000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Demographic features and prognostic factors of uterine carcinosarcoma: a study at a specialized center in Saudi Arabia"],"prefix":"10.3389","volume":"15","author":[{"given":"Wala","family":"Mehros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Aldosari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahaf","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wasan","family":"Alshareef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesal","family":"Hawsawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halah","family":"Fallata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatim","family":"Aljifree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Althubaiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2011.88","article-title":"Molecular markers and clinical behavior of uterine carcinosarcomas: Focus on the epithelial tumor component","volume":"24","author":"De Jong","year":"2011","journal-title":"Modern Pathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11070964","article-title":"Molecular basis of tumor heterogeneity in endometrial carcinosarcoma","volume":"11","author":"Leskel\u00e4","year":"2019","journal-title":"Cancers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12985-x","article-title":"Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma","volume":"10","author":"Gotoh","year":"2019","journal-title":"Nat Commun"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.02.010","article-title":"Integrated molecular characterization of uterine carcinosarcoma","volume":"31","author":"Cherniack","year":"2017","journal-title":"Cancer Cell"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1614120113","article-title":"Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition","volume":"113","author":"Zhao","year":"2016","journal-title":"Proc Natl Acad Sci United States Am"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.03.041","article-title":"Uterine carcinosarcoma: A review of the literature","volume":"137","author":"Cantrell","year":"2015","journal-title":"Gynecol Oncol"},{"key":"B7","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program\n          \n          \n          \n          2001"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ygyno.2013.05.015","article-title":"Uterine sarcomas","volume":"130","author":"Sutton","year":"2013","journal-title":"Gynecol Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2003.12.029","article-title":"Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma (1989 \u2013 1999)","volume":"93","author":"Brooks","year":"2004","journal-title":"Gynecol Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19861101)58:9<2003::aid-cncr2820580908>3.0.co;2-2","article-title":"An excess of uterine sarcomas after pelvic irradiation","volume":"58","author":"Meredith","year":"1986","journal-title":"Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1997.tb11992.x","article-title":"Uterine carcinosarcoma in association with tamoxifen therapy","volume":"104","author":"McCluggage","year":"1997","journal-title":"BJOG: Int J Obstet Gynaecol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.11.042","article-title":"Tumor characteristics and survival outcomes of women with tamoxifen-related uterine carcinosarcoma","volume":"144","author":"Matsuo","year":"2017","journal-title":"Gynecol Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2018.29.e22","article-title":"Trends of uterine carcinosarcoma in the United States","volume":"29","author":"Matsuo","year":"2018","journal-title":"J Gynecol Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.ygyno.2020.10.043","article-title":"Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity","volume":"160","author":"Matsuzaki","year":"2021","journal-title":"Gynecol Oncol"},{"key":"B15","unstructured":"Uterine neoplasm guidelines\n          \n          \n          \n          2020"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.03.017","article-title":"Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology\/Gynecologic Oncology Group study","volume":"145","author":"Creasman","year":"2017","journal-title":"Gynecol Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.08.014","article-title":"Patterns of care, predictors, and outcomes of chemotherapy for uterine carcinosarcoma: A National Cancer Database analysis","volume":"139","author":"Rauh-Hain","year":"2015","journal-title":"Gynecol Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ijgo.2009.02.010","article-title":"Revised FIGO staging for carcinoma of the endometrium","volume":"105","author":"Creasman","year":"2009","journal-title":"Int J Gynecol Obstet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/grf.0b013e31821ac635","article-title":"Uterine carcinosarcoma","volume":"54","author":"El-Nashar","year":"2011","journal-title":"Clin Obstet Gynecol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/aog.0b013e318176157c","article-title":"Uterine carcinosarcomas and Grade 3 endometrioid cancers","volume":"112","author":"Bansal","year":"2008","journal-title":"Obstet Gynecol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/igc.0b013e3181dc8292","article-title":"Ovarian and uterine carcinosarcomas: A comparative analysis of prognostic variables and survival outcomes","volume":"20","author":"Garg","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.epi-07-2567","article-title":"Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype","volume":"17","author":"McCullough","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.12892\/ejgo200204295","article-title":"The prognostic relevance of histological type in uterine sarcomas: A Cooperation Task Force (CTF) multivariate analysis of 249 cases","volume":"23","author":"Gadducci","year":"2002","journal-title":"Eur J Gynaecol Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.12659\/msm.941562","article-title":"Prognostic factors for uterine sarcoma and carcinosarcoma: Insights from a 10-year follow-up study","volume":"29","author":"Kotowicz","year":"2023","journal-title":"Med Sci Monitor"},{"key":"B25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ejogrb.2008.12.014","article-title":"Evaluation of prognostic factors and treatment outcomes in uterine carcinosarcoma","volume":"143","author":"Galaal","year":"2009","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","article-title":"The Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Levine","year":"2013","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.08.019","article-title":"TCGA molecular groups of endometrial cancer: Pooled data about prognosis","volume":"155","author":"Raffone","year":"2019","journal-title":"Gynecol Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/PGP.0b013e31823bb24d","article-title":"HER2\/neu as a potential target for immunotherapy in gynecologic carcinosarcomas","volume":"31","author":"Guzzo","year":"2012","journal-title":"Int J Gynecol Pathol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02558","article-title":"Trastuzumab deruxtecan for human epidermal growth factor receptor 2-expressing advanced or recurrent uterine carcinosarcoma (NCCH1615): the STATICE trial","volume":"41","author":"Nishikawa","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1594233\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T04:14:27Z","timestamp":1757045667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1594233\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":31,"alternative-id":["10.3389\/fonc.2025.1594233"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1594233","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,5]]},"article-number":"1594233"}}